Science Explorer Back to mapMap
Discussion
Topic · Surgery

Lymphadenopathy Diagnosis and Analysis

Lymphadenopathy Diagnosis and Analysis is a research topic within Surgery. Science Explorer counts 5.3k research works in it since 1950. 10.3% of them reached the world's top 10% most cited for their field and year.

This cluster of papers focuses on the analysis, diagnosis, and management of Kikuchi-Fujimoto Disease, particularly in pediatric patients and its association with systemic lupus erythematosus. It also explores the relationship between lymphadenopathy and COVID-19 vaccination, as well as the use of fine needle aspiration biopsy and FDG PET/CT in diagnosing and managing the disease.

  • Kikuchi-Fujimoto Disease
  • Lymphadenopathy
  • COVID-19 Vaccine
  • Pediatric
  • Diagnosis
  • Management
  • Fine Needle Aspiration Biopsy
  • Systemic Lupus Erythematosus
  • Histiocytic Necrotizing Lymphadenitis
  • FDG PET/CT
Research works
5.3k
fractional, since 1950
In the world top 10%
543
per year above
Top-10% rate
10.3%
share of its works in the world top 10%
Growth, 2018-21 → 2022-25
+31%
the tick is no change
Largest producer
United States
27% of the 10 largest, 2022-now
Lymphadenopathy Diagnosis and Analysis

This ranks research output and citation impact. It says nothing about the quality of diagnosis, treatment or care.

Which countries lead Lymphadenopathy Diagnosis and Analysis research?

By volume, the United States and India publish the most (273 and 176 works in 2022-now).

By volume, 2022-now

  1. 1 United States 273 works
  2. 2 India 176 works
  3. 3 China 159 works
  4. 4 Japan 88 works
  5. 5 Türkiye 64 works
  6. 6 Italy 60 works
  7. 7 United Kingdom 58 works
  8. 8 Germany 53 works
  9. 9 Spain 39 works
  10. 10 South Korea 32 works

How concentrated that is

The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.

United States: 27.3%India: 17.6%China: 15.9%Japan: 8.8%6 others listed: 30.5%27%largest
United States273 · 27.3%India176 · 17.6%China159 · 15.9%Japan88 · 8.8%6 others listed305 · 30.5%

Shares of the rows listed above, not of the whole node.

Which institutions lead Lymphadenopathy Diagnosis and Analysis research?

By volume in 2022-now, All India Institute of Medical Sciences publishes the most Lymphadenopathy Diagnosis and Analysis research, followed by Harvard University and Sağlık Bilimleri Üniversitesi.

By volume, 2022-now

  1. 1 All India Institute of Medical SciencesIndia 16 works
  2. 2 Harvard UniversityUnited States 13 works
  3. 3 Sağlık Bilimleri ÜniversitesiTürkiye 9 works
  4. 4 Mayo ClinicUnited States 8 works
  5. 5 Zhejiang UniversityChina 7 works
  6. 6 Capital Medical UniversityChina 6 works
  7. 7 Tel Aviv UniversityIsrael 6 works
  8. 8 Cornell UniversityUnited States 5 works
  9. 9 The University of Texas MD Anderson Cancer CenterUnited States 5 works
  10. 10 University of TorontoCanada 5 works

Who are the leading researchers in Lymphadenopathy Diagnosis and Analysis?

The most-cited researchers publishing on Lymphadenopathy Diagnosis and Analysis include Ahmedin Jemal, Hermann Brenner and Isabelle Soerjomataram.

  1. 1 Ahmedin Jemal United States 761k citations
  2. 2 Hermann Brenner Germany 343k citations
  3. 3 Isabelle Soerjomataram France 327k citations
  4. 4 Carlo La Vecchia Italy 258k citations
  5. 5 Didier Raoult France 232k citations
  6. 6 Dirk Schadendorf Germany 222k citations

Ranked by citations received across their whole record, among researchers with at least three works on this topic.

What are the most cited papers in Lymphadenopathy Diagnosis and Analysis?

The most cited paper in Lymphadenopathy Diagnosis and Analysis is "An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study" (Lucio Verdoni, Angelo Mazza, Annalisa Gervasoni et al., 2020), with 2,488 citations. Next come "Helicobacter pylori Infection and Gastric Lymphoma" (1,844) and "Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study" (1,806).

Most cited papers
#PaperReleasedCitations
1 An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study Lucio Verdoni, Angelo Mazza, Annalisa Gervasoni et al. · The Lancet Open access 13 May 2020 2,488
2 Helicobacter pylori Infection and Gastric Lymphoma Julie Parsonnet, Svein Hansen, Larissa Rodriguez et al. · New England Journal of Medicine Open access 5 May 1994 1,844
3 Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study Nicole M. Kuderer et al. · The Lancet Open access236 authors 28 May 2020 1,806
4 A Prognostic Score for Advanced Hodgkin's Disease Dirk Hasenclever et al. · New England Journal of Medicine Open access 19 Nov 1998 1,749
5 A Controlled Trial of a Human Papillomavirus Type 16 Vaccine Laura A. Koutsky, Kevin A. Ault, Cosette Marie Wheeler et al. · New England Journal of Medicine Open access 20 Nov 2002 1,615
All 100 most cited papers, with filters and sorting

Where is Lymphadenopathy Diagnosis and Analysis research done?

The largest centres of Lymphadenopathy Diagnosis and Analysis research in 2022-now are Beijing (China), Istanbul (Türkiye), Tokyo (Japan) and New Delhi (India). Among places with at least 20 works in it, it is an unusually large share of all research in Istanbul.

Largest cities, 2022-now

  1. 1 BeijingChina 22 works
  2. 2 IstanbulTürkiye 22 works
  3. 3 TokyoJapan 20 works
  4. 4 New DelhiIndia 20 works
  5. 5 New YorkUnited States 18 works
  6. 6 SeoulSouth Korea 15 works
  7. 7 LondonUnited Kingdom 15 works
  8. 8 HangzhouChina 13 works
  9. 9 BostonUnited States 13 works
  10. 10 HoustonUnited States 12 works

Where it is the local speciality

  1. IstanbulTR · 21.9 works3.2×
← less than its size predicts1×more →

Location quotient: how much more of its research is in Lymphadenopathy Diagnosis and Analysis than the world average.

See Lymphadenopathy Diagnosis and Analysis on the map

Where is the best place to study Lymphadenopathy Diagnosis and Analysis?

Among universities, judged by research, Harvard University, All India Institute of Medical Sciences and Sağlık Bilimleri Üniversitesi score highest, combining excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.

Excellenceshare of its work in the world top 10%, 2022-now and all time averaged
40%
Specialisationhow much of its work is in this field, counted up to 10× the world share
10%
Sizeits output in this field, on a log scale
30%
Growthoutput growth, counted from -20% to +20%
10%
Internationalshare of its work with a co-author abroad
10%
Each slider sets a weight; the share it gets of the score is beside it.
#UniversityScoreTop 10%SpecialisationWorksGrowth
1Harvard UniversityUnited States 75.713.7%3.0×13 +4.9%
2All India Institute of Medical SciencesIndia 69.48.0%10.9×16 +68.2%
3Sağlık Bilimleri ÜniversitesiTürkiye 27.73.3%12.0×9 +125.7%

Universities only. The score blends excellence (40%), size (30%), specialisation (10%), growth (10%), international reach (10%), 2022-now; growth compares 2018-21 with 2022-25 and counts up to +20%, since a jump from a small base is mostly noise.

Every institution in Lymphadenopathy Diagnosis and Analysis, country by country

Is Lymphadenopathy Diagnosis and Analysis research growing?

Output in 2022-2025 was 31% higher than in 2018-2021, peaking in 2022. The fastest-growing topics are Lymphadenopathy Diagnosis and Analysis.

still counting19801990200020102020
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Its share of all research

Growing output can still be a shrinking share: all of science grows. This is Lymphadenopathy Diagnosis and Analysis as a percentage of every work published that year, 0.0044% in 2024.

still counting0.0025%0.0050%0.0075%Lymphadenopathy Diagnosis and Analysis0.0058% in 202519801990200020102020

Fractional works of Lymphadenopathy Diagnosis and Analysis over all fractional works that year. How the balance of science has shifted.

How much of it reaches the world top 10%

Year by year.

still counting5%10%15%Lymphadenopathy Diagnosis and Analysis10.7% in 2025200020102020

Of each year's works in it, the share that reached the world's 10% most cited for their field and year. A field is the world for its own topics, so there is no other line to hold it against.

Which topics inside it are moving

Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.

Discussion

Ask a question or share a note about Lymphadenopathy Diagnosis and Analysis. Posts are plain text and can be reported.